Indies Pharma Jamaica recorded lower net profits for the year ended October 31, 2025, despite maintaining strong gross earnings.
The company reported net profit of $181.3 million, down from just over $221 million the previous year.
Revenue declined to $1.126 billion, compared with nearly $1.16 billion in 2024, while cost of sales fell to $350.9 million.
However, higher administrative and other expenses, which climbed to nearly $524 million, weighed on operating performance.
Finance costs declined slightly, while exchange gains were significantly lower.
Despite the drop in net profit, total comprehensive income surged to $616.3 million, driven by a $435 million revaluation gain on property, plant and equipment.
comments powered by Disqus
All feeds
